<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pigmented purpuric dermatoses (capillaritis)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pigmented purpuric dermatoses (capillaritis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pigmented purpuric dermatoses (capillaritis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amit Garg, MD, FAAD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H86150109"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The pigmented purpuric dermatoses (PPDs), also known as capillaritis, purpura simplex, and inflammatory purpura without vasculitis, are a group of chronic, benign, cutaneous eruptions characterized by the presence of petechiae, purpura, and increased skin pigmentation. PPDs most commonly occur on the lower extremities and may be asymptomatic or pruritic.</p><p>Familiarity with the clinical and pathologic findings of PPDs is useful for distinguishing them from cutaneous vasculitis and other disorders that may present with similar clinical features. The classic pathologic findings of PPDs include a perivascular mononuclear cell inflammatory infiltrate, erythrocyte extravasation, and hemosiderin deposition.</p><p>The diagnosis and treatment of PPDs will be reviewed here. Cutaneous vasculitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a> and  <a class="medical medical_review" href="/d/html/13785.html" rel="external">"Management of adults with idiopathic cutaneous small vessel vasculitis"</a>.)</p><p class="headingAnchor" id="H68508173"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Data are limited on the epidemiology of pigmented purpuric dermatoses (PPDs). Overall, these disorders are considered to be uncommon [<a href="#rid1">1</a>]. The major subtypes of PPD include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schamberg disease</strong> (the most common form of PPD [<a href="#rid2">2,3</a>], also known as progressive pigmentary purpura)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purpura annularis telangiectodes</strong> (also known as Majocchi disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmented purpuric lichenoid dermatitis of Gougerot and Blum</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen aureus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eczematid-like purpura of Doucas and Kapetanakis</strong></p><p></p><p>Rare, additional subtypes of PPD include itching purpura, unilateral linear capillaritis, and granulomatous pigmented purpura. Some authors have considered eczematid-like purpura of Doucas and Kapetanakis and itching purpura as a single entity [<a href="#rid4">4,5</a>].</p><p>Although PPD can develop at any age, age predilections have been observed in some subtypes [<a href="#rid2">2,4,6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schamberg disease </strong>– Middle-aged adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purpura annularis telangiectodes </strong>– Adolescents and young adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmented purpuric lichenoid dermatitis of Gougerot and Blum </strong>– Adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen aureus </strong>– Young adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eczematid-like purpura of Doucas and Kapetanakis </strong>– Middle-aged adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itching purpura </strong>– Middle-aged adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unilateral linear capillaritis </strong>– Young adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatous pigmented purpura </strong>– Adults</p><p></p><p>Children are not excluded from the development of PPDs [<a href="#rid2">2,9</a>]. Schamberg disease is the most common cause of petechiae in children [<a href="#rid2">2,3,9</a>], and has been documented in a child as young as one year [<a href="#rid10">10</a>]. In addition, there are multiple published reports of lichen aureus in children [<a href="#rid11">11-19</a>].</p><p>Data are insufficient to confirm whether sex predilections exist among PPDs, and two of the largest series have found conflicting results regarding whether Schamberg disease is more common in males or females [<a href="#rid5">5,7</a>].</p><p class="headingAnchor" id="H603931"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Multiple factors have been proposed as potential contributors to the development of pigmented purpuric dermatoses (PPDs), though none have been definitively proven. These include [<a href="#rid2">2,4,20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Venous insufficiency [<a href="#rid21">21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Gravitational dependency</p><p class="bulletIndent1"><span class="glyph">●</span>Aerobic exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Localized infection [<a href="#rid22">22</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol [<a href="#rid23">23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Chemical ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Contact allergens  (<a class="graphic graphic_table graphicRef89328" href="/d/graphic/89328.html" rel="external">table 1</a>) [<a href="#rid24">24-34</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Drugs  (<a class="graphic graphic_table graphicRef89329" href="/d/graphic/89329.html" rel="external">table 2</a>) [<a href="#rid35">35-47</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Flu vaccine [<a href="#rid48">48</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Coronavirus disease 2019 (COVID-19) vaccination [<a href="#rid49">49,50</a>]</p><p></p><p>In PPDs linked to drug exposure, times of onset ranging from one week to years after the start of drug treatment have been reported [<a href="#rid35">35-45</a>].</p><p>Associations between PPD and multiple systemic diseases have been proposed [<a href="#rid5">5</a>]. Examples of the most commonly cited associations include hyperlipidemia (granulomatous PPD) [<a href="#rid20">20,51-53</a>] and viral hepatitis [<a href="#rid54">54-57</a>]. However, the relationship between PPD and these disorders is uncertain. A case-control study of 60 patients with PPD and 230 controls did not find significant differences in the prevalence of hepatitis B or C among the patients with PPD [<a href="#rid58">58</a>]. PPDs are not manifestations of platelet abnormalities or bleeding disorders.</p><p>Some authors have considered PPD a form of a cutaneous T cell lymphoid dyscrasia based upon infrequent reports of PPD progressing to mycosis fungoides, similarities in the clinical and histologic features of PPD and mycosis fungoides, and the frequent detection of T cell monoclonality in lesions of PPD [<a href="#rid59">59</a>]. Further study is necessary to clarify the relationship between mycosis fungoides and PPD. (See <a class="local">'Relationship to mycosis fungoides'</a> below.)</p><p>There is a paucity of data on the pathogenic mechanisms that lead to the clinical findings of PPD, and thus, the mechanisms through which PPD develops are poorly understood. Three theories that have arisen based upon interpretation of the histologic and immunohistochemical findings in PPD are reviewed below: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular abnormalities </strong>–<strong> </strong>Extravasation of erythrocytes in the dermis is a characteristic pathologic feature of PPD. A state of capillary fragility has been postulated to contribute to capillary rupture and erythrocyte extravasation consistent with that observed in PPD [<a href="#rid2">2</a>]. Increased pressure in the cutaneous microvasculature secondary to venous stasis has also been proposed as a contributing factor [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell-mediated immunity </strong>– A mononuclear inflammatory cell infiltrate of varying extent is typically found in pathology specimens of PPD, and it is conceivable that a perivascular cell-mediated immune response could contribute to capillary damage and erythrocyte leakage [<a href="#rid61">61</a>]. The nature of the inflammatory infiltrate in Schamberg disease was investigated in a study of tissue specimens from five adults with the condition [<a href="#rid62">62</a>]. The infiltrate was primarily composed of CD4<sup>+</sup> lymphocytes and CD1a<sup>+</sup> dendritic cells. In addition, upregulation of adhesion molecules that could facilitate inflammatory cell trafficking was detected on infiltrating lymphocytes (LFA-1 and ICAM-1) and endothelial cells (ICAM-1 and ELAM-1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Humoral immunity </strong>–<strong> </strong>A potential role for immune complex disease in PPD has been suggested based upon reports documenting direct immunofluorescence findings of vascular deposits of C3, C1q, IgM, or IgA within lesional skin [<a href="#rid5">5,63,64</a>].</p><p></p><p>As a consequence of limited research, the role of each of these factors in the development of PPD remains uncertain. Additional studies are necessary to elucidate the pathophysiology of this disorder.</p><p class="headingAnchor" id="H603946"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The key clinical features of all pigmented purpuric dermatoses (PPDs) are petechiae or purpura, which reflect erythrocyte extravasation, and yellow to brown pigmented patches, which result from hemosiderin deposition within the dermis. The most common sites for PPDs are the lower extremities, although lesions also may develop in other areas. Infrequently, PPDs present as generalized eruptions. The palms, soles, genitalia, and mucosa are typically spared. </p><p>The clinical findings that distinguish the PPD subtypes are reviewed below.</p><p class="headingAnchor" id="H603960"><span class="h2">Schamberg disease (progressive pigmentary purpura)</span><span class="headingEndMark"> — </span>First described by Jay Frank Schamberg in 1901 [<a href="#rid65">65</a>], Schamberg disease presents with discrete, nonblanchable, red-brown purpuric patches that are usually a few millimeters to several millimeters in diameter, although some patches may reach several centimeters in breadth  (<a class="graphic graphic_picture graphicRef67127 graphicRef88989 graphicRef88990" href="/d/graphic/67127.html" rel="external">picture 1A-C</a>). Close inspection of the patches reveals nonpalpable pinpoint petechiae that were described by Schamberg as "pinpoint to pinhead sized reddish puncta, closely resembling grains of cayenne pepper" [<a href="#rid65">65</a>]. The most common site for involvement is the bilateral lower extremities (below the knees). The thighs and buttocks are also frequently involved. Less commonly, Schamberg disease presents with upper extremity or generalized involvement. Although Schamberg disease is usually asymptomatic, occasional patients experience mild pruritus.</p><p>The course of the condition is typically chronic, with numerous exacerbations and remissions. Spontaneous resolution also may occur [<a href="#rid5">5,9,66-70</a>]. In a retrospective series that included at least three years of follow-up data on each of the 45 patients with Schamberg disease, 62 percent cleared or improved and 38 percent remained stable or experienced worsening of symptoms [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H603968"><span class="h2">Purpura annularis telangiectodes (Majocchi disease)</span><span class="headingEndMark"> — </span>Initially described by Domenico Majocchi in 1896 [<a href="#rid71">71</a>], purpura annularis telangiectodes presents with nonblanchable, annular, 2 to 20 cm, symmetrical, purpuric, telangiectatic patches  (<a class="graphic graphic_picture graphicRef76569 graphicRef88991" href="/d/graphic/76569.html" rel="external">picture 2A-B</a>). Unilateral disease is reported in one patient [<a href="#rid72">72</a>]. Linear or arciform patches may also be present. Occasionally, atrophy is evident in the center of lesions [<a href="#rid73">73</a>]. </p><p>As with Schamberg disease, the most common site for involvement is the lower extremities [<a href="#rid74">74</a>]. Extension to the upper extremities and trunk may occur.</p><p>The cutaneous lesions of purpura annularis telangiectodes usually are asymptomatic. Occasionally, mild pruritus is present [<a href="#rid73">73,75</a>]. The course is chronic and characterized by relapses and remissions [<a href="#rid73">73</a>]. Individual lesions typically last several months. </p><p class="headingAnchor" id="H603985"><span class="h2">Pigmented purpuric lichenoid dermatitis of Gougerot and Blum</span><span class="headingEndMark"> — </span>Patients with pigmented purpuric lichenoid dermatitis of Gougerot and Blum develop small polygonal or round lichenoid purpuric papules that coalesce to form red-brown to violaceous plaques that are one to several centimeters in diameter  (<a class="graphic graphic_picture graphicRef88992" href="/d/graphic/88992.html" rel="external">picture 3</a>) [<a href="#rid76">76</a>]. The appearance of the plaques may resemble Kaposi sarcoma [<a href="#rid77">77</a>]. Like other subtypes of PPD, this eruption usually is found on the lower extremities. Rarely, there is involvement of the upper extremities or trunk. The course of pigmented purpuric lichenoid dermatitis of Gougerot and Blum tends to be chronic, although spontaneous remission may occur [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H604002"><span class="h2">Lichen aureus</span><span class="headingEndMark"> — </span>Lichen aureus (originally termed "lichen purpuricus") presents with the acute onset of distinctive, rust-yellow or gold colored lichenoid papules or circumscribed patches and plaques  (<a class="graphic graphic_picture graphicRef88993" href="/d/graphic/88993.html" rel="external">picture 4</a>) [<a href="#rid78">78</a>]. The term "lichen aureus" emphasizes the classic gold-brown color of the eruption [<a href="#rid79">79</a>]. Of note, lichen aureus also may present with copper-orange or violaceous lesions.</p><p>Lichen aureus most frequently occurs unilaterally on the lower extremities; bilateral involvement is less common [<a href="#rid11">11,15,80</a>]. Other reported distributions include upper extremity and trunk involvement; segmental, dermatomal, and Blaschkoid arrangements; and involvement that follows the course of superficial or deep veins [<a href="#rid80">80-85</a>]. Aberrant locations and distributions may occur more commonly in children [<a href="#rid11">11</a>].</p><p>Lichen aureus typically is asymptomatic. Occasionally, patients experience intense pruritus. </p><p>Lichen aureus tends to persist for multiple years, and, in some cases, is slowly progressive [<a href="#rid80">80,86</a>]. In a retrospective study of 42 patients with lichen aureus (age of onset 3 to 70 years), lesions tended to persist during the follow-up period of 3 months to 19 years [<a href="#rid80">80</a>]. Complete resolution was reported for only two patients. In contrast, spontaneous resolution was observed more frequently in a series of eight children with lichen aureus; five experienced resolution within two to six years (mean 3.4 years), two had reduced but continued lesions beyond four to five years, and one had persistent lesions at three years [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H604009"><span class="h2">Eczematid-like purpura of Doucas and Kapetanakis</span><span class="headingEndMark"> — </span>Eczematid-like purpura of Doucas and Kapetanakis is distinguished from other forms of PPD by the concomitant presence of eczematous features. The eruption usually begins with the insidious onset of groups of nonblanchable pinpoint red macules that evolve to a darker red or yellow-brown color over a few weeks [<a href="#rid6">6</a>]. The eruption typically begins on the lower extremities and may spread to the upper extremities or trunk. The face, neck, palms, and soles typically are spared. </p><p>Erythema and mild scale develop within the involved areas, resulting in an appearance that mimics eczema  (<a class="graphic graphic_picture graphicRef89316 graphicRef89392" href="/d/graphic/89316.html" rel="external">picture 5A-B</a>). Pruritus is common. Mild lichenification secondary to rubbing and scratching may be present. </p><p>Eczematid-like purpura of Doucas and Kapetanakis follows a fluctuating course. The eruption usually spontaneously resolves within several months to two years [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H604017"><span class="h2">Rare variants</span><span class="headingEndMark"> — </span>Rarely reported variants of PPD include itching purpura, unilateral linear capillaritis, and granulomatous pigmented purpura:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itching purpura </strong>– Itching purpura (also known as disseminated pruriginous angiodermatitis) is characterized by the acute onset of orange-brown to purpuric macules on the lower extremities. The lesions often subsequently become generalized. Unlike most other types of PPD, the condition is associated with severe pruritus [<a href="#rid87">87,88</a>]. Itching purpura has a chronic course, though spontaneous remissions occur. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unilateral linear capillaritis </strong>– Unilateral linear capillaritis (also known as segmental pigmented purpura and quadrantic capillaropathy) describes the development of pigmented purpura in a linear, dermatomal, or segmental distribution  (<a class="graphic graphic_picture graphicRef88997" href="/d/graphic/88997.html" rel="external">picture 6</a>) [<a href="#rid89">89-93</a>]. The condition primarily has been reported in young adults and children on the lower extremity or upper extremity [<a href="#rid89">89,90</a>]. The prognosis appears to be good; in a series of four males with lower extremity lesions, significant regression of skin lesions occurred within three years in all patients [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatous pigmented purpura </strong>– Approximately 20 cases of granulomatous pigmented purpura have been reported in the literature [<a href="#rid20">20,51-53,94-100</a>]. The condition usually presents with multiple erythematous to brown purpuric macules or papules and is distinguished from other types of PPD by the detection of a granulomatous infiltrate on histopathology  (<a class="graphic graphic_picture graphicRef88994 graphicRef88995" href="/d/graphic/88994.html" rel="external">picture 7A-B</a>). The most common sites of involvement are the dorsum of the feet and the legs. Less frequently, wrists and hands have been affected. A blaschkoid distribution has also been reported [<a href="#rid101">101</a>]. </p><p></p><p class="bulletIndent1">Many of the reported cases have occurred in patients who also had hyperlipidemia, prompting some authors to question whether a relationship between these disorders exists [<a href="#rid51">51-53,98,99</a>]. The cutaneous lesions may persist for years [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H604051"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The pigmented purpuric dermatoses (PPDs) subtypes share several histopathologic features, including [<a href="#rid5">5,59,102</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A superficial, perivascular, inflammatory infiltrate (primarily CD4<sup>+</sup> lymphocytes with occasional dendritic cells and macrophages)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endothelial cell proliferation and edema; narrowing of vessel lumens</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extravasation of erythrocytes in the papillary dermis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variable degree of hemosiderin deposition in macrophages in the dermis (particularly in mature lesions)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte exocytosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variable mild vacuolar degeneration at the basal layer</p><p></p><p>Histochemical stains that stain iron, such as the Perls or Fontana Masson stain, are useful for highlighting hemosiderin deposition in the superficial dermis. Of note, features of leukocytoclastic vasculitis (eg, leukocytoclasia and fibrinoid necrosis of vessel walls) are absent. (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Diagnostic criteria'</a>.)</p><p>Depending on the clinical subtype of PPD, additional histopathologic features may be present:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schamberg disease</strong> – Variable degree of epidermal spongiosis [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmented purpuric lichenoid dermatitis of Gougerot and Blum</strong> – Band-like (lichenoid), lymphocytic infiltrate in the upper dermis with or without epidermal spongiosis [<a href="#rid103">103</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen aureus</strong> – Dense, lichenoid, lymphocytic infiltrate in the upper dermis and at the dermal-epidermal junction; variable degree of lymphocyte exocytosis; with or without a Grenz zone (an area of uninvolved connective tissue that separates the dermal infiltrate from the epidermis) [<a href="#rid80">80</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eczematoid purpura of Doucas and Kapetanakis</strong> – Epidermal spongiosis [<a href="#rid6">6</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itching purpura</strong> – Epidermal spongiosis, marked inflammatory response that includes neutrophils [<a href="#rid102">102</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatous pigmented purpura</strong> – Mononuclear cell infiltrate accompanied by a granulomatous infiltrate in the papillary dermis [<a href="#rid94">94</a>]</p><p></p><p class="headingAnchor" id="H604058"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>No laboratory abnormalities are associated with pigmented purpuric dermatoses (PPDs). Laboratory tests that assess for platelet abnormalities, coagulopathies, or acute phase reactants are expected to be normal. </p><p class="headingAnchor" id="H604065"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The presence of discrete or circumscribed, nonpalpable, purpuric macules and patches (particularly on the lower extremity) with petechiae and yellow-brown pigmentation suggests the possibility of pigmented purpuric dermatoses (PPDs), particularly Schamberg disease, the classic form of PPD. Palpable lesions exhibiting similar features suggest variants of PPD that often present with papules or plaques, such as lichen aureus, eczematid-like purpura of Doucas and Kapetanakis, and granulomatous pigmented purpura. The diagnosis is usually made through clinical inspection and the recognition of classic morphologic features.</p><p>Dermoscopy may be a useful adjunct to clinical inspection with the naked eye. A review of 32 patients with PPD suggests that dermoscopic findings in lesions of pigmented purpura may include coppery-red pigmentation in the background; a brown network; linear vessels; round to oval, red dots, globules, and patches; brown globules and dots; linear brown line; and follicular openings [<a href="#rid104">104</a>]. Dermoscopy may also help distinguish purpuric mycosis fungoides (PMF) from PPD; in a study of 28 patients with PMF and 13 patients with PPD, fine, short, linear vessels and spermatozoa-like structures were more common in PMF lesions [<a href="#rid105">105</a>].</p><p>A skin biopsy is useful when the diagnosis remains uncertain following clinical examination. Biopsies may help to distinguish PPD from disorders in the differential diagnosis, such as cutaneous vasculitis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H604091"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of pigmented purpuric dermatoses (PPDs) consists of other cutaneous lesions that may present with petechiae, purpura, eczematous features, or localized hyperpigmentation related to hemosiderin deposition. A careful clinical assessment and biopsy (when needed) can aid in distinguishing PPD from other disorders. Stasis dermatitis, cutaneous vasculitis, traumatic purpura, and mycosis fungoides are among the disorders most likely to be confused with PPD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stasis dermatitis </strong>– Stasis dermatitis shares both clinical and pathologic features with PPD. Stasis dermatitis usually presents on the lower extremities with insidious onset of eczematous patches that progress to red-brown or brawny colored irregular patches  (<a class="graphic graphic_picture graphicRef70596 graphicRef72689" href="/d/graphic/70596.html" rel="external">picture 8A-B</a>). Associated varicosities and leg edema are often present. The medial ankle is the most common site of initial involvement. Like PPD, the pathology findings of stasis dermatitis include epidermal spongiosis, a perivascular lymphocytic infiltrate, dilated dermal capillaries with intimal thickening, and hemosiderin within dermal macrophages. Clinicians should be aware that stasis dermatitis and PPD may coexist. (See  <a class="medical medical_review" href="/d/html/13670.html" rel="external">"Stasis dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous vasculitis </strong>–<strong> </strong>Cutaneous leukocytoclastic vasculitis presents with the acute onset of <strong>palpable purpura</strong>, often primarily involving the lower extremities and other dependent areas of the body. Hemorrhagic bullae and brown pigmentation consistent with hemosiderin deposition in the skin also may be present  (<a class="graphic graphic_picture graphicRef51770 graphicRef65932 graphicRef56272 graphicRef57440" href="/d/graphic/51770.html" rel="external">picture 9A-D</a>). The palpable nature of this disorder is useful for distinguishing it from Schamberg disease and purpura annularis telangiectodes, which present with <strong>nonpalpable</strong> petechiae and/or purpura. A skin biopsy can distinguish vasculitis from PPD; the vessel destruction, leukocytoclasia, and fibrinoid necrosis characteristic of vasculitis are not found in PPD. (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traumatic purpura </strong>– Injury to the skin may result in the development of purpuric patches. Traumatic purpura are much less persistent than PPDs, typically evolving and resolving over the course of a few weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycosis fungoides </strong>– PPD is sometimes difficult to distinguish from mycosis fungoides. Infrequently, purpura is an initial manifestation of mycosis fungoides, and the two disorders can have overlapping histologic features (eg, lichenoid infiltrate, lymphocytes invading the epidermis). In cases in which the clinical features suggest PPD, but pathologic examination raises the question of mycosis fungoides, distinguishing between the conditions can be challenging. The detection of large intraepidermal groups of lymphocytes or many lymphocytes in the spinous layer of the epidermis favor a diagnosis of mycosis fungoides [<a href="#rid106">106</a>]. (See <a class="local">'Relationship to mycosis fungoides'</a> below and  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p>Additional disorders that may enter the differential diagnosis of a patient with specific forms of PPD include scurvy, dermatitis, and Kaposi sarcoma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scurvy </strong>– The purpuric lesions of scurvy may be confused with the scattered petechiae and purpura of Schamberg disease  (<a class="graphic graphic_picture graphicRef51219 graphicRef76282" href="/d/graphic/51219.html" rel="external">picture 10A-B</a>). The detection of perifollicular purpura, corkscrew-shaped hairs, bleeding gums, and a dietary history of reduced vitamin C intake support a diagnosis of scurvy. (See  <a class="medical medical_review" href="/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eczematous dermatitis </strong>– Additional disorders that should be considered in the differential diagnosis of eczematid-like purpura of Doucas and Kapetanakis include atopic dermatitis, nummular eczema, and allergic contact dermatitis  (<a class="graphic graphic_picture graphicRef64525 graphicRef55375 graphicRef66792 graphicRef81478" href="/d/graphic/64525.html" rel="external">picture 11A-D</a>). These disorders can be clinically distinguished from this subtype of PPD by the absence of petechiae, purpura, and the yellow-brown pigmentation characteristic of PPDs. In addition, the pathologic findings of atopic dermatitis and allergic contact dermatitis do not include erythrocyte extravasation and hemosiderin deposition. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kaposi sarcoma </strong>– Kaposi sarcoma may mimic the presentation of pigmented purpuric lichenoid dermatitis of Gougerot and Blum. Cutaneous lesions of Kaposi sarcoma appear as violaceous macules, papules, plaques, or nodules, most commonly on the lower extremities, head, neck, and oral mucosa  (<a class="graphic graphic_picture graphicRef69584" href="/d/graphic/69584.html" rel="external">picture 12</a>). The last three sites are typically spared in PPD. Kaposi sarcoma is easily distinguished from PPD through pathology findings of vascular proliferation, dermal spindle cells, and vascular slits. (See  <a class="medical medical_review" href="/d/html/7729.html" rel="external">"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/8033.html" rel="external">"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H604121"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Pigmented purpuric dermatoses (PPDs) are benign conditions that are often asymptomatic. Thus, treatment is not always necessary and reassurance is an acceptable course of management for most patients. Treatment is generally considered for patients with associated symptoms and for patients who are distressed by the cosmetic appearance of the skin lesions.</p><p>Because most data on the efficacy of treatments are derived from case reports and small case series and spontaneous resolution of PPD is possible, the best approach to treatment remains uncertain. In our experience, the response to treatment is unpredictable and often poor. Given the benign nature of PPDs, the risk-benefit ratio of treatment always should be considered.</p><p>When patients desire treatment, we typically begin with measures to reduce exacerbating factors or topical corticosteroids due to the relative safety of these interventions. We reserve other interventions for patients with extensive involvement or topical corticosteroid-refractory lesions who also have a strong desire for additional treatment. </p><p class="headingAnchor" id="H604129"><span class="h2">First-line interventions</span><span class="headingEndMark"> — </span>Our first-line therapies for PPDs are nonpharmacologic interventions and topical corticosteroids.</p><p class="headingAnchor" id="H604143"><span class="h3">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Non-drug interventions for PPD are aimed at eliminating or reducing potential contributing factors. In patients in whom the development of a PPD appears to correlate with exposure to a medication or contact allergen, discontinuation of exposure to the potential inciting agent should be implemented whenever feasible. (See <a class="local">'Etiology and pathogenesis'</a> above.)</p><p>Due to the theory that increased vascular pressure may contribute to capillary leakage in PPDs, many clinicians, including ourselves, often have patients with PPDs on the lower extremities wear supportive stockings, particularly if concomitant signs of venous stasis are present. However, the efficacy of this measure for accelerating resolution of the PPD is unproven.</p><p class="headingAnchor" id="H604151"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>Topical corticosteroids have been used for PPD based upon the histologic evidence that PPD is an inflammatory process. Although some case reports and case series have documented improvement in PPD during topical corticosteroid therapy, the response to treatment is inconsistent [<a href="#rid4">4,5,9,13,51,107-109</a>]. Randomized controlled trials of topical corticosteroid therapy for PPD have not been performed. </p><p>When treating with topical corticosteroids, we typically prescribe application of a medium potency or high potency topical corticosteroid once to twice daily to affected areas for four to six weeks  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. If no improvement is detected within this period, we discontinue topical corticosteroid treatment. </p><p>Cutaneous atrophy is a potential adverse effect of topical corticosteroid treatment. The adverse effects of this treatment are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H37661212"><span class="h2">Second-line intervention</span><span class="headingEndMark"> — </span>Phototherapy is a well-tolerated skin-directed treatment that appears to be of value for some patients with PPD. We consider phototherapy for patients who fail topical corticosteroid therapy or for patients for whom topical therapy is impractical due to extensive involvement. Data on the long-term benefit of phototherapy after treatment cessation are limited.</p><p class="headingAnchor" id="H84969765"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>Case reports and small case series have documented improvement in PPDs with ultraviolet B (UVB) or psoralen plus ultraviolet A (PUVA) phototherapy. Multiple treatment sessions are required. The repeated visits required for phototherapy are a deterrent to treatment for some patients (see  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Narrowband ultraviolet B </strong>– In a prospective uncontrolled study of five patients with Schamberg disease and one patient with purpura annularis telangiectodes, treatment with narrowband ultraviolet B (NBUVB) three times per week led to a good response (more than 75 percent reduction in petechiae and pigmentation) in all patients within 24 to 28 treatment sessions [<a href="#rid110">110</a>]. Subsequently, maintenance treatments were given twice per week for three weeks followed by once per week for three weeks. The two patients who relapsed during the one-year follow-up period improved with additional sessions of NBUVB treatment. </p><p></p><p class="bulletIndent1">Case reports and case series describe other patients with PPD [<a href="#rid111">111-114</a>] (including children [<a href="#rid9">9,114,115</a>]) who seemed to respond well to NBUVB phototherapy. For example, patients with pigmented purpuric lichenoid dermatitis of Gougerot and Blum have achieved improvement or lesion clearance during NBUVB phototherapy [<a href="#rid9">9,116</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoralen plus ultraviolet A </strong>– Psoralen plus ultraviolet A (PUVA) phototherapy involves the administration of a psoralen prior to irradiation with ultraviolet A (UVA) light. In a series of 11 adults treated with PUVA for PPD (five with Schamberg disease, five with pigmented lichenoid dermatitis of Gougerot and Blum, and one with eczematid-like purpura of Doucas and Kapetanakis), all patients achieved lesion clearance [<a href="#rid117">117</a>]. Moreover, dramatic reductions in CD4<sup>+</sup> and CD1a cells and adhesion molecule expression were detected following PUVA therapy. A separate series of seven adults with pigmented purpuric lichenoid dermatitis of Gougerot and Blum also seemed to demonstrate benefit of PUVA; all patients achieved clearance of skin lesions within 7 to 20 PUVA treatments [<a href="#rid63">63</a>]. Two patients who relapsed one month after treatment cessation responded to a second course of treatment. </p><p></p><p class="bulletIndent1">Improvement in PPD during PUVA also has been reported in case reports of patients with Schamberg disease [<a href="#rid118">118</a>], lichen aureus [<a href="#rid119">119</a>], and unilateral linear capillaritis [<a href="#rid90">90</a>]. </p><p></p><p>Potential adverse effects of phototherapy include sunburns, blistering, pruritus, and skin aging. Increased risk for skin cancer has been reported in psoriasis patients who have received high numbers of PUVA treatments. The side effects of phototherapy are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)", section on 'Short- and long-term adverse effects'</a> and  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H84970397"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>Multiple other therapies have been utilized for PPD. Only <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a> has been evaluated in a randomized trial.</p><p class="headingAnchor" id="H37661236"><span class="h3">Pentoxifylline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">Pentoxifylline</a> may have beneficial effects on Schamberg disease. Pentoxifylline is a drug that inhibits adhesion of leukocytes to endothelial cells and can stimulate vascular endothelium to release PGI<sub>2</sub>, which inhibits platelet adhesion and aggregation [<a href="#rid85">85</a>]. Pentoxifylline is also used for the management of lower extremity chronic venous disease. </p><p>A single-blind randomized trial of 112 adults with moderate to severe Schamberg disease compared eight weeks of treatment with <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a> (400 mg three times per day) to topical <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate 0.05% cream (applied twice daily for eight weeks) [<a href="#rid120">120</a>]. Whereas 34 patients in the pentoxifylline group (61 percent) had a statistically significant reduction in a disease severity score after two months, this occurred in only 12 of 56 patients in the corticosteroid group (21 percent). By four months after treatment cessation, statistically significant reductions in the severity score remained in 14 patients in the pentoxifylline group and 8 patients in the corticosteroid group. Whether cosmetically significant responses were obtained is unclear.</p><p>Case reports and small case series of <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a> for Schamberg disease have documented both marked clinical improvement in patients with 300 mg per day or 400 mg three times daily [<a href="#rid121">121,122</a>] and treatment failure in patients treated with 300 to 600 mg per day [<a href="#rid123">123,124</a>]. Further studies are necessary to confirm the clinical value of the drug for PPD. Partial improvement following combination therapy with pentoxifylline and prostacyclin (PGI<sub>2</sub>) was reported in a patient with segmental lichen aureus [<a href="#rid85">85</a>]. </p><p>Treatment with <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a> is generally well tolerated. Gastrointestinal symptoms (eg, nausea, vomiting) are the most common adverse effects.</p><p class="headingAnchor" id="H84970404"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other therapies that have been reported to be beneficial for PPD in small numbers of patients include <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> [<a href="#rid125">125</a>], calcium dobesilate (500 mg twice daily) [<a href="#rid126">126</a>], <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> (0.5 mg twice daily) [<a href="#rid127">127,128</a>], <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> ointment [<a href="#rid129">129</a>], <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> cream [<a href="#rid73">73</a>], photodynamic therapy [<a href="#rid130">130</a>], pulse dye laser [<a href="#rid131">131,132</a>], and alexandrite laser [<a href="#rid133">133</a>]. Immunosuppressants such as systemic glucocorticoids [<a href="#rid111">111</a>], <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid134">134</a>], and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid73">73</a>] have been used successfully, but generally are not indicated given the potential adverse effects of these agents and the minimal data to support their efficacy.</p><p>An oral bioflavonoid (rutoside) 50 mg twice daily and ascorbic acid (500 mg twice daily) has been reported to improve PPD [<a href="#rid6">6,135,136</a>]. In a two center retrospective case series of 35 patients with Schamberg disease receiving rutoside 50 mg twice daily and 1000 mg ascorbic acid once daily with a mean treatment duration of 8.2 months, 71 percent experienced complete clearance and 20 percent experienced improvement of greater than 50 percent. Nine participants (25 percent) relapsed after discontinuation. Seven of these patients responded to reinitiation of rutoside and ascorbic acid. Those with shorter disease duration had better responses, shorter time to response, and lower risk of recurrence [<a href="#rid136">136</a>].</p><p class="headingAnchor" id="H22917785"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>In general, pigmented purpuric dermatoses (PPDs) are benign, chronic conditions. Eruptions persist, wax and wane, or slowly progress, and may clear spontaneously over a period of months to years. The clinical courses of specific forms of PPD are reviewed above. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H22917793"><span class="h2">Relationship to mycosis fungoides</span><span class="headingEndMark"> — </span>Infrequent reports of patients in whom a diagnosis of PPD preceded a diagnosis of mycosis fungoides or in whom mycosis fungoides presented with clinical features of PPD, as well as studies that have found shared clinical and histologic features between the two disorders, have led to uncertainty about the relationship between mycosis fungoides and PPD [<a href="#rid59">59,106,137-144</a>]. As an example, in a study of 56 biopsy specimens from patients with PPD, 29 (52 percent) exhibited pathologic patterns that have been associated with mycosis fungoides [<a href="#rid106">106</a>]. </p><p>Similar to mycosis fungoides, monoclonal expansion of T cells is frequently detected in patients with PPD [<a href="#rid15">15,59,106,145</a>]. The authors of one study found that patients diagnosed with PPD who had monoclonal expansion were more likely to exhibit clinical and pathologic features similar to those of mycosis fungoides and proposed that PPD may represent a form of cutaneous T cell lymphoid dyscrasia [<a href="#rid59">59</a>]. In another study, 8 of 12 PPD biopsy specimens that had lichenoid histologic patterns exhibited monoclonality [<a href="#rid106">106</a>]. </p><p>The clinical significance of monoclonal expansion in PPD is uncertain; clinical experience suggests that the development of mycosis fungoides after an initial diagnosis of PPD is rare. A review of 23 patients with lichen aureus found that although 8 of 16 patients who had T cell receptor-γ gene rearrangement performed had a monoclonal T cell population, after a mean follow-up of 102 months (range 11 to 382 months), none of the patients in the study developed mycosis fungoides [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H22917824"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Because of the potential association between PPD and mycosis fungoides, patients with atypical presentations and patients who demonstrate clinical or histologic features that suggest a possibility of mycosis fungoides require close clinical follow-up. In particular, the possibility of mycosis fungoides should be considered when patients present with large confluent patches or plaques with reticular arrangements, violaceous hue, or pruritus that have persisted or relapsed over the course of several years [<a href="#rid37">37,137</a>]. Case reports suggest that males may be more likely to have overlapping mycosis fungoides and PPD [<a href="#rid59">59</a>]. (See <a class="local">'Relationship to mycosis fungoides'</a> above.)</p><p>Due to the lack of data on the risk for mycosis fungoides in patients with classic presentations of PPD, the need for follow-up of patients with classic presentations of PPD is unclear. It is generally thought that the risk for mycosis fungoides in this population is low. As a precaution, we perform skin examinations on patients with PPD once yearly.</p><p class="headingAnchor" id="H84970213"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>No preventive measures have been established for pigmented purpuric dermatoses (PPDs).</p><p class="headingAnchor" id="H84970252"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pigmented purpuric dermatoses (PPDs) are uncommon benign cutaneous disorders that are clinically characterized by petechiae or purpura (secondary to erythrocyte extravasation) and localized hyperpigmentation (secondary to hemosiderin deposition in the skin). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The five major types of PPD are Schamberg disease, purpura annularis telangiectodes, pigmented purpuric lichenoid dermatitis of Gougerot and Blum, lichen aureus, and eczematid-like purpura of Doucas and Kapetanakis. Schamberg disease is the most common type of PPD. PPDs may affect both adults and children. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of PPDs are poorly understood. Factors such as venous hypertension, systemic diseases, drugs, and contact allergens may contribute to the development of PPDs. Vascular abnormalities, cell-mediated immunity, and humoral immunity have been proposed as pathogenic mechanisms. (See <a class="local">'Etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PPDs usually can be made through clinical examination. No laboratory abnormalities are associated with PPDs. Skin biopsies are useful for confirming a PPD when the diagnosis is uncertain. (See <a class="local">'Histopathology'</a> above and <a class="local">'Laboratory findings'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The response of PPDs to treatment is unpredictable. Most patients with PPD do not require treatment. Treatment is considered for patients who desire treatment due to associated symptoms or patients who are bothered by the cosmetic appearance of lesions. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data on the efficacy of treatments for PPD are limited. Our initial approach involves the elimination of drugs or contact allergens that appear to have induced PPD and the use of supportive stockings for patients with concomitant signs of venous stasis. For patients who desire further treatment, we suggest a four to six week course of a medium or high potency topical corticosteroid applied to affected areas (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'First-line interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who desire treatment, but fail to respond to topical corticosteroid therapy, or for whom topical therapy is impractical due to extensive involvement, we suggest treatment with phototherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options for treatment include narrowband ultraviolet B (NBUVB) and psoralen plus ultraviolet A (PUVA) phototherapy. (See <a class="local">'Second-line intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of other treatments have been used for the management of PPD. <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">Pentoxifylline</a> may be beneficial in patients with Schamberg disease. (See <a class="local">'Other interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no definitive guidelines for the follow-up of patients with PPD. We typically follow patients with atypical clinical features or with histologic features that are suspicious for mycosis fungoides closely due to a possible relationship between mycosis fungoides and PPD. We perform skin examinations on other patients with PPD once yearly. (See <a class="local">'Prognosis and follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sardana K, Sarkar R, Sehgal VN. Pigmented purpuric dermatoses: an overview. Int J Dermatol 2004; 43:482.</a></li><li><a class="nounderline abstract_t">Tristani-Firouzi P, Meadows KP, Vanderhooft S. Pigmented purpuric eruptions of childhood: a series of cases and review of literature. Pediatr Dermatol 2001; 18:299.</a></li><li><a class="nounderline abstract_t">Torrelo A, Requena C, Mediero IG, Zambrano A. Schamberg's purpura in children: a review of 13 cases. J Am Acad Dermatol 2003; 48:31.</a></li><li><a class="nounderline abstract_t">Newton RC, Raimer SS. Pigmented purpuric eruptions. Dermatol Clin 1985; 3:165.</a></li><li><a class="nounderline abstract_t">Ratnam KV, Su WP, Peters MS. Purpura simplex (inflammatory purpura without vasculitis): a clinicopathologic study of 174 cases. J Am Acad Dermatol 1991; 25:642.</a></li><li><a class="nounderline abstract_t">DOUCAS C, KAPETANAKIS J. Eczematid-like purpura. Dermatologica 1953; 106:86.</a></li><li><a class="nounderline abstract_t">RANDALL SJ, KIERLAND RR, MONTGOMERY H. Pigmented purpuric eruptions. AMA Arch Derm Syphilol 1951; 64:177.</a></li><li><a class="nounderline abstract_t">Sherertz EF. Pigmented purpuric eruptions. Semin Thromb Hemost 1984; 10:190.</a></li><li><a class="nounderline abstract_t">Coulombe J, Jean SE, Hatami A, et al. Pigmented purpuric dermatosis: clinicopathologic characterization in a pediatric series. Pediatr Dermatol 2015; 32:358.</a></li><li><a class="nounderline abstract_t">Zvulunov A, Avinoach I, Hatskelzon L, Halevy S. Pigmented purpuric dermatosis (Schamberg's purpura) in an infant. Dermatol Online J 1999; 5:2.</a></li><li><a class="nounderline abstract_t">Gelmetti C, Cerri D, Grimalt R. Lichen aureus in childhood. Pediatr Dermatol 1991; 8:280.</a></li><li><a class="nounderline abstract_t">Kahana M, Levy A, Schewach-Millet M, et al. Lichen aureus occurring in childhood. Int J Dermatol 1985; 24:666.</a></li><li><a class="nounderline abstract_t">Moche J, Glassman S, Modi D, Grayson W. Segmental lichen aureus: a report of two cases treated with methylprednisolone aceponate. Australas J Dermatol 2011; 52:e15.</a></li><li><a class="nounderline abstract_t">Böhm M, Bonsmann G, Luger TA. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br J Dermatol 2004; 151:519.</a></li><li><a class="nounderline abstract_t">Fink-Puches R, Wolf P, Kerl H, Cerroni L. Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides. Arch Dermatol 2008; 144:1169.</a></li><li><a class="nounderline abstract_t">Kim MJ, Kim BY, Park KC, Youn SW. A case of childhood lichen aureus. Ann Dermatol 2009; 21:393.</a></li><li><a class="nounderline abstract_t">Yazdi AS, Mayser P, Sander CA. Lichen aureus with clonal T cells in a child possibly induced by regular consumption of an energy drink. J Cutan Pathol 2008; 35:960.</a></li><li><a class="nounderline abstract_t">Fujita H, Iguchi M, Ikari Y, Asahina A. Lichen aureus on the back in a 6-year-old girl. J Dermatol 2007; 34:148.</a></li><li><a class="nounderline abstract_t">Rubio FA, Robayna G, Herranz P, et al. Abdominal Lichen aureus in a child. Pediatr Dermatol 1997; 14:411.</a></li><li><a class="nounderline abstract_t">Wong WR, Kuo TT, Chen MJ, Chan HL. Granulomatous variant of chronic pigmented purpuric dermatosis: report of two cases. Br J Dermatol 2001; 145:162.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee GW, Son JW, et al. Venous Insufficiency is a Clear Provoker of Pigmented Purpuric Dermatosis. Ann Dermatol 2022; 34:34.</a></li><li><a class="nounderline abstract_t">Satoh T, Yokozeki H, Nishioka K. Chronic pigmented purpura associated with odontogenic infection. J Am Acad Dermatol 2002; 46:942.</a></li><li><a class="nounderline abstract_t">Bonnet U, Selle C, Isbruch K, Isbruch K. Recurrent purpura due to alcohol-related Schamberg's disease and its association with serum immunoglobulins: a longitudinal observation of a heavy drinker. J Med Case Rep 2016; 10:301.</a></li><li><a class="nounderline abstract_t">Pratt M, Taraska V. Disperse blue dyes 106 and 124 are common causes of textile dermatitis and should serve as screening allergens for this condition. Am J Contact Dermat 2000; 11:30.</a></li><li><a class="nounderline abstract_t">van der Veen JP, Neering H, de Haan P, Bruynzeel DP. Pigmented purpuric clothing dermatitis due to Disperse Blue 85. Contact Dermatitis 1988; 19:222.</a></li><li><a class="nounderline abstract_t">Foti C, Elia G, Filotico R, Angelini G. Purpuric clothing dermatitis due to Disperse Yellow 27. Contact Dermatitis 1998; 39:273.</a></li><li><a class="nounderline abstract_t">Lazarov A, Cordoba M. The purpuric patch test in patients with allergic contact dermatitis from azo dyes. Contact Dermatitis 2000; 42:23.</a></li><li><a class="nounderline abstract_t">Shimunes E. Purpuric allergic contact dermatitis to paraphenylenediamine. Contact Dermatitis 1978; 4:225.</a></li><li><a class="nounderline abstract_t">Roed-Petersen J, Clemmensen OJ, Menné T, Larsen E. Purpuric contact dermatitis from black rubber chemicals. Contact Dermatitis 1988; 18:166.</a></li><li><a class="nounderline abstract_t">Schmidt H, Larsen FS, Larsen PO, Søgaard H. Petechial reaction following patch testing with cobalt. Contact Dermatitis 1980; 6:91.</a></li><li><a class="nounderline abstract_t">Laurberg G, Christiansen JV. Purpuric allergic contact dermatitis to epoxy resin. Contact Dermatitis 1984; 11:186.</a></li><li><a class="nounderline abstract_t">Koch P, Baum HP, John S. Purpuric patch test reaction and venulitis due to methyl methacrylate in a dental prosthesis. Contact Dermatitis 1996; 34:213.</a></li><li><a class="nounderline abstract_t">de Waard-van der Spek FB, Oranje AP. Purpura caused by Emla is of toxic origin. Contact Dermatitis 1997; 36:11.</a></li><li><a class="nounderline abstract_t">van Joost T, van Ulsen J, Vuzevski VD, et al. Purpuric contact dermatitis to benzoyl peroxide. J Am Acad Dermatol 1990; 22:359.</a></li><li><a class="nounderline abstract_t">Abeck D, Gross GE, Kuwert C, et al. Acetaminophen-induced progressive pigmentary purpura (Schamberg's disease). J Am Acad Dermatol 1992; 27:123.</a></li><li><a class="nounderline abstract_t">Kwon SJ, Lee CW. Figurate purpuric eruptions on the trunk: acetaminophen-induced rashes. J Dermatol 1998; 25:756.</a></li><li><a class="nounderline abstract_t">Lipsker D, Cribier B, Heid E, Grosshans E. [Cutaneous lymphoma manifesting as pigmented, purpuric capillaries]. Ann Dermatol Venereol 1999; 126:321.</a></li><li><a class="nounderline abstract_t">Peterson WC Jr, Manick KP. Purpuric eruptions associated with use of carbromal and meprobamate. Arch Dermatol 1967; 95:40.</a></li><li><a class="nounderline abstract_t">Nishioka K, Katayama I, Masuzawa M, et al. Drug-induced chronic pigmented purpura. J Dermatol 1989; 16:220.</a></li><li><a class="nounderline abstract_t">Voelter WW. Pigmented purpuric dermatosis-like reaction to topical fluorouracil. Arch Dermatol 1983; 119:875.</a></li><li><a class="nounderline abstract_t">Adams BB, Gadenne AS. Glipizide-induced pigmented purpuric dermatosis. J Am Acad Dermatol 1999; 41:827.</a></li><li><a class="nounderline abstract_t">Tsao H, Lerner LH. Pigmented purpuric eruption associated with injection medroxyprogesterone acetate. J Am Acad Dermatol 2000; 43:308.</a></li><li><a class="nounderline abstract_t">Koçak AY, Akay BN, Heper AO. Sildenafil-induced pigmented purpuric dermatosis. Cutan Ocul Toxicol 2013; 32:91.</a></li><li><a class="nounderline abstract_t">Nishioka K, Sarashi C, Katayama I. Chronic pigmented purpura induced by chemical substances. Clin Exp Dermatol 1980; 5:213.</a></li><li><a class="nounderline abstract_t">Kaplan R, Meehan SA, Leger M. A case of isotretinoin-induced purpura annularis telangiectodes of Majocchi and review of substance-induced pigmented purpuric dermatosis. JAMA Dermatol 2014; 150:182.</a></li><li><a class="nounderline abstract_t">Schetz D, Kocić I. A new adverse drug reaction--Schamberg's disease caused by amlodipine administration--a case report. Br J Clin Pharmacol 2015; 80:1477.</a></li><li><a class="nounderline abstract_t">Miraglia E, Bianchini D, Panetta C, et al. A case of lichenoid pigmented purpuric dermatitis of Gougerot-Blum after amoxicillin. Ital J Dermatol Venerol 2021; 156:74.</a></li><li><a class="nounderline abstract_t">Baklouti M, Sellami K, Chaabouni R, et al. Flu vaccine-induced purpura annularis telangiectodes of Majocchi. Therapie 2022; 77:496.</a></li><li><a class="nounderline abstract_t">Atak MF, Farabi B, Kalelioglu MB, Rao BK. Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration. J Cosmet Dermatol 2022; 21:435.</a></li><li><a class="nounderline abstract_t">Di Bartolomeo L, Vaccaro F, Borgia F, et al. Capillaritis as cutaneous adverse reaction to SARS-COV-2 primary and booster vaccination: A series of eight cases. J Eur Acad Dermatol Venereol 2023; 37:e297.</a></li><li><a class="nounderline abstract_t">Kaplan J, Burgin S, Sepehr A. Granulomatous pigmented purpura: report of a case and review of the literature. J Cutan Pathol 2011; 38:984.</a></li><li><a class="nounderline abstract_t">Macquarrie EK, Pasternak S, Torok M, et al. Persistent pigmented purpuric dermatitis: granulomatous variant. J Cutan Pathol 2011; 38:979.</a></li><li><a class="nounderline abstract_t">Tato BP, Marinero Escobedo S, Pérez González YC, et al. Granulomatous variant of pigmented purpuric dermatosis. Am J Dermatopathol 2012; 34:746.</a></li><li><a class="nounderline abstract_t">Gupta G, Holmes SC, Spence E, Mills PR. Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection. J Am Acad Dermatol 2000; 43:937.</a></li><li><a class="nounderline abstract_t">Dessoukey MW, Abdel-Dayem H, Omar MF, Al-Suweidi NE. Pigmented purpuric dermatosis and hepatitis profile: a report on 10 patients. Int J Dermatol 2005; 44:486.</a></li><li><a class="nounderline abstract_t">Sawamura D, Ohata Y, Shibaki A, Shimizu H. Pigmented purpuric dermatosis in mixed cryoglobulinaemia associated with rheumatoid arthritis and hepatitis C infection. Acta Derm Venereol 2005; 85:460.</a></li><li><a class="nounderline abstract_t">Raslan HM, Ezzat WM, Abd El Hamid MF, et al. Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt. East Mediterr Health J 2009; 15:692.</a></li><li><a class="nounderline abstract_t">Ehsani AH, Ghodsi SZ, Nourmohammad-Pour P, et al. Pigmented purpura dermatosis and viral hepatitis: a case-control study. Australas J Dermatol 2013; 54:225.</a></li><li><a class="nounderline abstract_t">Magro CM, Schaefer JT, Crowson AN, et al. Pigmented purpuric dermatosis: classification by phenotypic and molecular profiles. Am J Clin Pathol 2007; 128:218.</a></li><li><a class="nounderline abstract_t">Shelley WB, Swaminathan R, Shelley ED. Lichen aureus: a hemosiderin tattoo associated with perforator vein incompetence. J Am Acad Dermatol 1984; 11:260.</a></li><li><a class="nounderline abstract_t">Aiba S, Tagami H. Immunohistologic studies in Schamberg's disease. Evidence for cellular immune reaction in lesional skin. Arch Dermatol 1988; 124:1058.</a></li><li><a class="nounderline abstract_t">Ghersetich I, Lotti T, Bacci S, et al. Cell infiltrate in progressive pigmented purpura (Schamberg's disease): immunophenotype, adhesion receptors, and intercellular relationships. Int J Dermatol 1995; 34:846.</a></li><li><a class="nounderline abstract_t">Krizsa J, Hunyadi J, Dobozy A. PUVA treatment of pigmented purpuric lichenoid dermatitis (Gougerot-Blum). J Am Acad Dermatol 1992; 27:778.</a></li><li><a class="nounderline abstract_t">Iwatsuki K, Aoshima T, Tagami H, et al. Immunofluorescence study in purpura pigmentosa chronica. Acta Derm Venereol 1980; 60:341.</a></li><li><a class="nounderline abstract_t">Schamberg JF. A peculiar progressive pigmentary disease of the skin. Br J Dermatol 1901; 13:1.</a></li><li><a class="nounderline abstract_t">Roehm HR. Progressive pigmentary dermatosis (Schamberg). Clin Pediatr (Phila) 1968; 7:307.</a></li><li><a class="nounderline abstract_t">Hersh CS, Shwayder TA. Unilateral progressive pigmentary purpura (Schamberg's disease) in a 15-year-old boy. J Am Acad Dermatol 1991; 24:651.</a></li><li><a class="nounderline abstract_t">Draelos ZK, Hansen RC. Schamberg's purpura in children: case study and literature review. Clin Pediatr (Phila) 1987; 26:659.</a></li><li><a class="nounderline abstract_t">Kerem E, Branski D, Gross-Kieselstein E, et al. Chronic pigmented purpura: a case report of Schamberg's disease. Clin Pediatr (Phila) 1987; 26:657.</a></li><li><a class="nounderline abstract_t">Nichamin SJ, Brough AJ. Chronic progressive pigmentary purpura. Purpura annulares telangiectodes of Majocchi-Schamberg. Am J Dis Child 1968; 116:429.</a></li><li><a class="nounderline abstract_t">Majocchi D. Sopra una dermatosi telangiectode non ancora descritta: purpura annularis. G Ital Mal Ven 1896; 31:263.</a></li><li><a class="nounderline abstract_t">Wang A, Shuja F, Chan A, Wasko C. Unilateral purpura annularis telangiectodes of majocchi in an elderly male: an atypical presentation. Dermatol Online J 2013; 19:19263.</a></li><li><a class="nounderline abstract_t">Hoesly FJ, Huerter CJ, Shehan JM. Purpura annularis telangiectodes of Majocchi: case report and review of the literature. Int J Dermatol 2009; 48:1129.</a></li><li><a class="nounderline abstract_t">Kim HJ, Skidmore RA, Woosley JT. Pigmented purpura over the lower extremities. Purpura annularis telangiectodes of Majocchi. Arch Dermatol 1998; 134:1477, 1480.</a></li><li><a class="nounderline abstract_t">Hale EK. Purpura annularis telangiectodes of Majocchi. Dermatol Online J 2003; 9:17.</a></li><li><a class="nounderline abstract_t">Gougerot H, Blum P. Purpura angioscleux prurigeneux avec elements lichenoides. Bull Soc Franc Derm Syph 1925; 32:161.</a></li><li><a class="nounderline abstract_t">Wong RC, Solomon AR, Field SI, Anderson TF. Pigmented purpuric lichenoid dermatitis of Gougerot-Blum mimicking Kaposi's sarcoma. Cutis 1983; 31:406.</a></li><li><a class="nounderline abstract_t">Marten RH. Case for diagnosis. Trans St. John's Hosp Dermatol Soc 1958; 30:98.</a></li><li><a class="nounderline abstract_t">Calnan CD. Lichen aureus. Br J Dermatol 1960; 72:373.</a></li><li><a class="nounderline abstract_t">Price ML, Jones EW, Calnan CD, MacDonald DM. Lichen aureus: a localized persistent form of pigmented purpuric dermatitis. Br J Dermatol 1985; 112:307.</a></li><li><a class="nounderline abstract_t">Mishra D, Maheshwari V. Segmental lichen aureus in a child. Int J Dermatol 1991; 30:654.</a></li><li><a class="nounderline abstract_t">Leal-Khouri S, Sherman LD, Mallory SB. Segmental eruption in an 8-year-old girl. Pediatr Dermatol 1992; 9:154.</a></li><li><a class="nounderline abstract_t">Abramovits W, Landau JW, Lowe NJ. A report of two patients with lichen aureus. Arch Dermatol 1980; 116:1183.</a></li><li><a class="nounderline abstract_t">Ruiz-Esmenjaud J, Dahl MV. Segmental lichen aureus: onset associated with trauma and puberty. Arch Dermatol 1988; 124:1572.</a></li><li><a class="nounderline abstract_t">Lee HW, Lee DK, Chang SE, et al. Segmental lichen aureus: combination therapy with pentoxifylline and prostacyclin. J Eur Acad Dermatol Venereol 2006; 20:1378.</a></li><li><a class="nounderline abstract_t">Graham RM, English JS, Emmerson RW. Lichen aureus--a study of twelve cases. Clin Exp Dermatol 1984; 9:393.</a></li><li><a class="nounderline abstract_t">MOSTO SJ, CASALA AM. DISSEMINATED PRURIGINOUS ANGIODERMATITIS: ITCHING PURPURA. Arch Dermatol 1965; 91:351.</a></li><li><a class="nounderline abstract_t">Pravda DJ, Moynihan GD. Itching purpura. Cutis 1980; 25:147.</a></li><li><a class="nounderline abstract_t">Riordan CA, Darley C, Markey AC, et al. Unilateral linear capillaritis. Clin Exp Dermatol 1992; 17:182.</a></li><li><a class="nounderline abstract_t">Ma HJ, Zhao G, Liu W, et al. Unilateral linear capillaritis: two unusual Chinese cases. Eur J Dermatol 2007; 17:160.</a></li><li><a class="nounderline abstract_t">Mar A, Fergin P, Hogan P. Unilateral pigmented purpuric eruption. Australas J Dermatol 1999; 40:211.</a></li><li><a class="nounderline abstract_t">Taketuchi Y, Chinen T, Ichikawa Y, Ito M. Two cases of unilateral pigmented purpuric dermatosis. J Dermatol 2001; 28:493.</a></li><li><a class="nounderline abstract_t">Abdullah L, Abbas O. Dermacase. Can you identify this condition? Unilateral linear capillaritis. Can Fam Physician 2011; 57:563.</a></li><li><a class="nounderline abstract_t">Saito R, Matsuoka Y. Granulomatous pigmented purpuric dermatosis. J Dermatol 1996; 23:551.</a></li><li><a class="nounderline abstract_t">Lin WL, Kuo TT, Shih PY, et al. Granulomatous variant of chronic pigmented purpuric dermatoses: report of four new cases and an association with hyperlipidaemia. Clin Exp Dermatol 2007; 32:513.</a></li><li><a class="nounderline abstract_t">Kerns MJ, Mallatt BD, Shamma HN. Granulomatous pigmented purpura: an unusual histological variant. Am J Dermatopathol 2009; 31:77.</a></li><li><a class="nounderline abstract_t">Lee SH, Kwon JE, Lee KG, Roh MR. Granulomatous variant of chronic pigmented purpuric dermatosis associated with hyperlipidaemia. J Eur Acad Dermatol Venereol 2010; 24:1243.</a></li><li><a class="nounderline abstract_t">Battle LR, Shalin SC, Gao L. Granulomatous pigmented purpuric dermatosis. Clin Exp Dermatol 2015; 40:387.</a></li><li><a class="nounderline abstract_t">Hanson C, Fischer R, Fraga G, Rajpara A. Granulomatous pigmented purpuric dermatosis: an unusual variant associated with hyperlipidemia. Dermatol Online J 2014; 21.</a></li><li><a class="nounderline abstract_t">MacKenzie AI, Biswas A. Granulomatous pigmented purpuric dermatosis: report of a case with atypical clinical presentation including dermoscopic findings. Am J Dermatopathol 2015; 37:311.</a></li><li><a class="nounderline abstract_t">Carvajal D, Quiroz C, Morales C, Fernández J. Granulomatous pigmented purpuric dermatosis: report of a Latin-American case with blaschkoid distribution. An Bras Dermatol 2019; 94:582.</a></li><li class="breakAll">Weedon D. The vasculopathic reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.195.</li><li><a class="nounderline abstract_t">Fishman HC. Pigmented purpuric lichenoid dermatitis of Gougerot-Blum. Cutis 1982; 29:260.</a></li><li><a class="nounderline abstract_t">Ozkaya DB, Emiroglu N, Su O, et al. Dermatoscopic findings of pigmented purpuric dermatosis. An Bras Dermatol 2016; 91:584.</a></li><li><a class="nounderline abstract_t">Nasimi M, Bonabiyan M, Lajevardi V, et al. Pigmented purpuric dermatoses versus purpuric mycosis fungoides: Clinicopathologic similarities and new insights into dermoscopic features. Australas J Dermatol 2022; 63:81.</a></li><li><a class="nounderline abstract_t">Toro JR, Sander CA, LeBoit PE. Persistent pigmented purpuric dermatitis and mycosis fungoides: simulant, precursor, or both? A study by light microscopy and molecular methods. Am J Dermatopathol 1997; 19:108.</a></li><li><a class="nounderline abstract_t">Lor P, Krueger U, Kempf W, et al. Monoclonal rearrangement of the T cell receptor gamma-chain in lichenoid pigmented purpuric dermatitis of gougerot-blum responding to topical corticosteroid therapy. Dermatology 2002; 205:191.</a></li><li><a class="nounderline abstract_t">Rudolph RI. Lichen aureus. J Am Acad Dermatol 1983; 8:722.</a></li><li><a class="nounderline abstract_t">Risikesan J, Sommerlund M, Ramsing M, et al. Successful Topical Treatment of Pigmented Purpuric Lichenoid Dermatitis of Gougerot-Blum in a Young Patient: A Case Report and Summary of the Most Common Pigmented Purpuric Dermatoses. Case Rep Dermatol 2017; 9:169.</a></li><li><a class="nounderline abstract_t">Fathy H, Abdelgaber S. Treatment of pigmented purpuric dermatoses with narrow-band UVB: a report of six cases. J Eur Acad Dermatol Venereol 2011; 25:603.</a></li><li><a class="nounderline abstract_t">Lasocki AL, Kelly RI. Narrowband UVB therapy as an effective treatment for Schamberg's disease. Australas J Dermatol 2008; 49:16.</a></li><li><a class="nounderline abstract_t">Gudi VS, White MI. Progressive pigmented purpura (Schamberg's disease) responding to TL01 ultraviolet B therapy. Clin Exp Dermatol 2004; 29:683.</a></li><li><a class="nounderline abstract_t">Karadag AS, Bilgili SG, Onder S, Calka O. Two cases of eczematid-like purpura of Doucas and Kapetanakis responsive to narrow band ultraviolet B treatment. Photodermatol Photoimmunol Photomed 2013; 29:97.</a></li><li><a class="nounderline abstract_t">Dhali TK, Chahar M, Haroon MA. Phototherapy as an effective treatment for Majocchi's disease--case report. An Bras Dermatol 2015; 90:96.</a></li><li><a class="nounderline abstract_t">Can B, Turkoglu Z, Kavala M, et al. Successful treatment of generalized childhood Schamberg's disease with narrowband ultraviolet B therapy. Photodermatol Photoimmunol Photomed 2011; 27:216.</a></li><li><a class="nounderline abstract_t">Kocaturk E, Kavala M, Zindanci I, et al. Narrowband UVB treatment of pigmented purpuric lichenoid dermatitis (Gougerot-Blum). Photodermatol Photoimmunol Photomed 2009; 25:55.</a></li><li><a class="nounderline abstract_t">Lotti T, Ghersetich I, Panconesi E. Why should we use PUVA treatment in pigmented purpuric lichenoid dermatitis? J Am Acad Dermatol 1994; 30:145.</a></li><li><a class="nounderline abstract_t">Seckin D, Yazici Z, Senol A, Demircay Z. A case of Schamberg's disease responding dramatically to PUVA treatment. Photodermatol Photoimmunol Photomed 2008; 24:95.</a></li><li><a class="nounderline abstract_t">Ling TC, Goulden V, Goodfield MJ. PUVA therapy in lichen aureus. J Am Acad Dermatol 2001; 45:145.</a></li><li><a class="nounderline abstract_t">Panda S, Malakar S, Lahiri K. Oral pentoxifylline vs topical betamethasone in Schamberg disease: a comparative randomized investigator-blinded parallel-group trial. Arch Dermatol 2004; 140:491.</a></li><li><a class="nounderline abstract_t">Kano Y, Hirayama K, Orihara M, Shiohara T. Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36:827.</a></li><li><a class="nounderline abstract_t">Wahba-Yahav AV. Schamberg's purpura: association with persistent hepatitis B surface antigenemia and treatment with pentoxifylline. Cutis 1994; 54:205.</a></li><li><a class="nounderline abstract_t">Basak PY, Ergin S. Should pentoxifylline be regarded as an effective treatment for Schamberg's disease? J Am Acad Dermatol 2001; 44:548.</a></li><li><a class="nounderline abstract_t">Burkhart CG, Burkhart KM. Pentoxifylline for Schamberg's disease. J Am Acad Dermatol 1998; 39:298.</a></li><li><a class="nounderline abstract_t">Tamaki K, Yasaka N, Osada A, et al. Successful treatment of pigmented purpuric dermatosis with griseofulvin. Br J Dermatol 1995; 132:159.</a></li><li><a class="nounderline abstract_t">Agrawal SK, Gandhi V, Bhattacharya SN. Calcium dobesilate (Cd) in pigmented purpuric dermatosis (PPD): a pilot evaluation. J Dermatol 2004; 31:98.</a></li><li><a class="nounderline abstract_t">Geller M. Benefit of colchicine in the treatment of Schamberg's disease. Ann Allergy Asthma Immunol 2000; 85:246.</a></li><li><a class="nounderline abstract_t">Cavalcante MLLL, Masuda PY, Brito FF, et al. Schamberg's disease: case report with therapeutic success by using colchicine. An Bras Dermatol 2017; 92:246.</a></li><li><a class="nounderline abstract_t">Murota H, Katayama I. Lichen aureus responding to topical tacrolimus treatment. J Dermatol 2011; 38:823.</a></li><li><a class="nounderline abstract_t">Kim SK, Kim EH, Kim YC. Treatment of pigmented purpuric dermatosis with topical photodynamic therapy. Dermatology 2009; 219:184.</a></li><li><a class="nounderline abstract_t">Hong DK, Chang IK, Lee Y, et al. Treatment of segmental lichen aureus with a pulsed-dye laser: new treatment options for lichen aureus. Eur J Dermatol 2013; 23:891.</a></li><li><a class="nounderline abstract_t">Arreola Jauregui IE, López Zaldo JB, Huerta Rivera G, et al. A case of lichen aureus successfully treated with 595 nm wavelength pulsed-dye laser. J Cosmet Dermatol 2020; 19:657.</a></li><li><a class="nounderline abstract_t">Fernandez-Nieto D, Jimenez-Cauhe J, Ortega-Quijano D, et al. Treatment of segmental lichen aureus in the pediatric age with a 755 nm alexandrite picosecond laser. A new therapeutic approach for pigmented purpuric dermatosis. J Dtsch Dermatol Ges 2020; 18:1201.</a></li><li><a class="nounderline abstract_t">Okada K, Ishikawa O, Miyachi Y. Purpura pigmentosa chronica successfully treated with oral cyclosporin A. Br J Dermatol 1996; 134:180.</a></li><li><a class="nounderline abstract_t">Reinhold U, Seiter S, Ugurel S, Tilgen W. Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients. J Am Acad Dermatol 1999; 41:207.</a></li><li><a class="nounderline abstract_t">Schober SM, Peitsch WK, Bonsmann G, et al. Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis. J Dtsch Dermatol Ges 2014; 12:1112.</a></li><li><a class="nounderline abstract_t">Barnhill RL, Braverman IM. Progression of pigmented purpura-like eruptions to mycosis fungoides: report of three cases. J Am Acad Dermatol 1988; 19:25.</a></li><li><a class="nounderline abstract_t">Martínez W, del Pozo J, Vázquez J, et al. Cutaneous T-cell lymphoma presenting as disseminated, pigmented, purpura-like eruption. Int J Dermatol 2001; 40:140.</a></li><li><a class="nounderline abstract_t">Ugajin T, Satoh T, Yokozeki H, Nishioka K. Mycosis fungoides presenting as pigmented purpuric eruption. Eur J Dermatol 2005; 15:489.</a></li><li><a class="nounderline abstract_t">Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 2004; 18:397.</a></li><li><a class="nounderline abstract_t">Georgala S, Katoulis AC, Symeonidou S, et al. Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature. J Eur Acad Dermatol Venereol 2001; 15:62.</a></li><li><a class="nounderline abstract_t">Puddu P, Ferranti G, Frezzolini A, et al. Pigmented purpura-like eruption as cutaneous sign of mycosis fungoides with autoimmune purpura. J Am Acad Dermatol 1999; 40:298.</a></li><li><a class="nounderline abstract_t">Cather JC, Farmer A, Jackow C, et al. Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. J Am Acad Dermatol 1998; 39:858.</a></li><li><a class="nounderline abstract_t">Crowson AN, Magro CM, Zahorchak R. Atypical pigmentary purpura: a clinical, histopathologic, and genotypic study. Hum Pathol 1999; 30:1004.</a></li><li><a class="nounderline abstract_t">Ladrigan MK, Poligone B. The spectrum of pigmented purpuric dermatosis and mycosis fungoides: atypical T-cell dyscrasia. Cutis 2014; 94:297.</a></li></ol></div><div id="topicVersionRevision">Topic 13757 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15230884" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pigmented purpuric dermatoses: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576402" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pigmented purpuric eruptions of childhood: a series of cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522367" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Schamberg's purpura in children: a review of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4092379" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pigmented purpuric eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1791222" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Purpura simplex (inflammatory purpura without vasculitis): a clinicopathologic study of 174 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13060054" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Eczematid-like purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14856408" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pigmented purpuric eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6474193" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pigmented purpuric eruptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25690369" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pigmented purpuric dermatosis: clinicopathologic characterization in a pediatric series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673445" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pigmented purpuric dermatosis (Schamberg's purpura) in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1792198" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lichen aureus in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4086135" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lichen aureus occurring in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605087" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Segmental lichen aureus: a report of two cases treated with methylprednisolone aceponate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327576" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794462" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lichen aureus: clinicopathologic features, natural history, and relationship to mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523830" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A case of childhood lichen aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18494820" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lichen aureus with clonal T cells in a child possibly induced by regular consumption of an energy drink.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239157" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lichen aureus on the back in a 6-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336821" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Abdominal Lichen aureus in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453929" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Granulomatous variant of chronic pigmented purpuric dermatosis: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35221593" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Venous Insufficiency is a Clear Provoker of Pigmented Purpuric Dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063496" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic pigmented purpura associated with odontogenic infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27799068" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recurrent purpura due to alcohol-related Schamberg's disease and its association with serum immunoglobulins: a longitudinal observation of a heavy drinker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10684387" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Disperse blue dyes 106 and 124 are common causes of textile dermatitis and should serve as screening allergens for this condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3191687" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pigmented purpuric clothing dermatitis due to Disperse Blue 85.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840281" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Purpuric clothing dermatitis due to Disperse Yellow 27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644021" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The purpuric patch test in patients with allergic contact dermatitis from azo dyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/710100" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Purpuric allergic contact dermatitis to paraphenylenediamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3365970" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Purpuric contact dermatitis from black rubber chemicals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398281" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Petechial reaction following patch testing with cobalt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6499418" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Purpuric allergic contact dermatitis to epoxy resin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8833467" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Purpuric patch test reaction and venulitis due to methyl methacrylate in a dental prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034681" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Purpura caused by Emla is of toxic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137465" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Purpuric contact dermatitis to benzoyl peroxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1619063" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acetaminophen-induced progressive pigmentary purpura (Schamberg's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9863291" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Figurate purpuric eruptions on the trunk: acetaminophen-induced rashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421934" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : [Cutaneous lymphoma manifesting as pigmented, purpuric capillaries].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6016305" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Purpuric eruptions associated with use of carbromal and meprobamate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507607" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug-induced chronic pigmented purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6685460" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pigmented purpuric dermatosis-like reaction to topical fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534660" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Glipizide-induced pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906656" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pigmented purpuric eruption associated with injection medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22780873" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sildenafil-induced pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6449323" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic pigmented purpura induced by chemical substances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284887" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A case of isotretinoin-induced purpura annularis telangiectodes of Majocchi and review of substance-induced pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256559" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A new adverse drug reaction--Schamberg's disease caused by amlodipine administration--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31760725" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A case of lichenoid pigmented purpuric dermatitis of Gougerot-Blum after amoxicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34175124" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Flu vaccine-induced purpura annularis telangiectodes of Majocchi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34791786" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36437470" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Capillaritis as cutaneous adverse reaction to SARS-COV-2 primary and booster vaccination: A series of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752054" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Granulomatous pigmented purpura: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21899591" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Persistent pigmented purpuric dermatitis: granulomatous variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23007717" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Granulomatous variant of pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044828" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941437" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pigmented purpuric dermatosis and hepatitis profile: a report on 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159747" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pigmented purpuric dermatosis in mixed cryoglobulinaemia associated with rheumatoid arthritis and hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731785" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190427" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pigmented purpura dermatosis and viral hepatitis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638655" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pigmented purpuric dermatosis: classification by phenotypic and molecular profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480927" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lichen aureus: a hemosiderin tattoo associated with perforator vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3291778" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Immunohistologic studies in Schamberg's disease. Evidence for cellular immune reaction in lesional skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647662" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cell infiltrate in progressive pigmented purpura (Schamberg's disease): immunophenotype, adhesion receptors, and intercellular relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430408" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : PUVA treatment of pigmented purpuric lichenoid dermatitis (Gougerot-Blum)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6163282" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Immunofluorescence study in purpura pigmentosa chronica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A peculiar progressive pigmentary disease of the skin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5689686" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Progressive pigmentary dermatosis (Schamberg).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2033147" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Unilateral progressive pigmentary purpura (Schamberg's disease) in a 15-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3315387" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Schamberg's purpura in children: case study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677535" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic pigmented purpura: a case report of Schamberg's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5697979" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chronic progressive pigmentary purpura. Purpura annulares telangiectodes of Majocchi-Schamberg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sopra una dermatosi telangiectode non ancora descritta: purpura annularis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021442" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Unilateral purpura annularis telangiectodes of majocchi in an elderly male: an atypical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19775410" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Purpura annularis telangiectodes of Majocchi: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9828887" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pigmented purpura over the lower extremities. Purpura annularis telangiectodes of Majocchi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594590" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Purpura annularis telangiectodes of Majocchi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Purpura angioscleux prurigeneux avec elements lichenoides</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6851635" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pigmented purpuric lichenoid dermatitis of Gougerot-Blum mimicking Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Case for diagnosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lichen aureus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3978038" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lichen aureus: a localized persistent form of pigmented purpuric dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1938081" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Segmental lichen aureus in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603742" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Segmental eruption in an 8-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7425668" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A report of two patients with lichen aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3421736" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Segmental lichen aureus: onset associated with trauma and puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062089" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Segmental lichen aureus: combination therapy with pentoxifylline and prostacyclin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6744650" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Lichen aureus--a study of twelve cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14275499" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : DISSEMINATED PRURIGINOUS ANGIODERMATITIS: ITCHING PURPURA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7357881" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Itching purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451296" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Unilateral linear capillaritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337403" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Unilateral linear capillaritis: two unusual Chinese cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570559" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Unilateral pigmented purpuric eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603391" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Two cases of unilateral pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21571719" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Dermacase. Can you identify this condition? Unilateral linear capillaritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8854588" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Granulomatous pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535280" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Granulomatous variant of chronic pigmented purpuric dermatoses: report of four new cases and an association with hyperlipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155731" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Granulomatous pigmented purpura: an unusual histological variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236201" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Granulomatous variant of chronic pigmented purpuric dermatosis associated with hyperlipidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25522174" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Granulomatous pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756477" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Granulomatous pigmented purpuric dermatosis: an unusual variant associated with hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698941" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Granulomatous pigmented purpuric dermatosis: report of a case with atypical clinical presentation including dermoscopic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777360" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Granulomatous pigmented purpuric dermatosis: report of a Latin-American case with blaschkoid distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777360" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Granulomatous pigmented purpuric dermatosis: report of a Latin-American case with blaschkoid distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7067496" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pigmented purpuric lichenoid dermatitis of Gougerot-Blum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27828629" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dermatoscopic findings of pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34905635" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pigmented purpuric dermatoses versus purpuric mycosis fungoides: Clinicopathologic similarities and new insights into dermoscopic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129694" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Persistent pigmented purpuric dermatitis and mycosis fungoides: simulant, precursor, or both? A study by light microscopy and molecular methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218245" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Monoclonal rearrangement of the T cell receptor gamma-chain in lichenoid pigmented purpuric dermatitis of gougerot-blum responding to topical corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6863634" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Lichen aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29033823" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Successful Topical Treatment of Pigmented Purpuric Lichenoid Dermatitis of Gougerot-Blum in a Young Patient: A Case Report and Summary of the Most Common Pigmented Purpuric Dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21492246" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Treatment of pigmented purpuric dermatoses with narrow-band UVB: a report of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186840" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Narrowband UVB therapy as an effective treatment for Schamberg's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550157" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Progressive pigmented purpura (Schamberg's disease) responding to TL01 ultraviolet B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458394" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Two cases of eczematid-like purpura of Doucas and Kapetanakis responsive to narrow band ultraviolet B treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25672304" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Phototherapy as an effective treatment for Majocchi's disease--case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21729171" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Successful treatment of generalized childhood Schamberg's disease with narrowband ultraviolet B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19152519" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Narrowband UVB treatment of pigmented purpuric lichenoid dermatitis (Gougerot-Blum).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7506273" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Why should we use PUVA treatment in pigmented purpuric lichenoid dermatitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353090" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A case of Schamberg's disease responding dramatically to PUVA treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423854" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : PUVA therapy in lichen aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096387" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Oral pentoxifylline vs topical betamethasone in Schamberg disease: a comparative randomized investigator-blinded parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146559" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Successful treatment of Schamberg's disease with pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7813245" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Schamberg's purpura: association with persistent hepatitis B surface antigenemia and treatment with pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11209142" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Should pentoxifylline be regarded as an effective treatment for Schamberg's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704856" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pentoxifylline for Schamberg's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756136" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Successful treatment of pigmented purpuric dermatosis with griseofulvin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15160862" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Calcium dobesilate (Cd) in pigmented purpuric dermatosis (PPD): a pilot evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030283" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Benefit of colchicine in the treatment of Schamberg's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538889" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Schamberg's disease: case report with therapeutic success by using colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352316" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Lichen aureus responding to topical tacrolimus treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19590170" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Treatment of pigmented purpuric dermatosis with topical photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24185327" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Treatment of segmental lichen aureus with a pulsed-dye laser: new treatment options for lichen aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298789" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A case of lichen aureus successfully treated with 595 nm wavelength pulsed-dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32656950" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Treatment of segmental lichen aureus in the pediatric age with a 755 nm alexandrite picosecond laser. A new therapeutic approach for pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8745912" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Purpura pigmentosa chronica successfully treated with oral cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426890" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: an open pilot study in 3 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25482694" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3403742" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Progression of pigmented purpura-like eruptions to mycosis fungoides: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328399" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Cutaneous T-cell lymphoma presenting as disseminated, pigmented, purpura-like eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280306" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Mycosis fungoides presenting as pigmented purpuric eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196152" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Clinicopathological spectrum of mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451328" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025852" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Pigmented purpura-like eruption as cutaneous sign of mycosis fungoides with autoimmune purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9810916" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10492033" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Atypical pigmentary purpura: a clinical, histopathologic, and genotypic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566571" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : The spectrum of pigmented purpuric dermatosis and mycosis fungoides: atypical T-cell dyscrasia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
